Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy

Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy

US Patent 10765711 · Granted Sep 8, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CTLA-4 antibodies and methods of use thereof2025
Anti-CTLA-4 antibodies and methods of use thereof2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Imaging systems and methods2025
Hybrid nail gun2025
Neoantigens and uses thereof for treating cancer2025
Neoantigens and uses thereof for treating cancer2025